Ketamine vs. Classic Psychedelics: A Comprehensive Guide

When deciding between options for mental health care, labels can blur. Here’s a plain-language guide — shaped by how Dr. Ben Yudkoff explains it — to compare classic psychedelics (psilocybin, LSD, DMT, iboga/ibogaine), ketamine (and esketamine, the FDA-approved nasal spray Spravato), and MDMA (an empathogen). Our goal at Lumin Health is simple: give you enough clarity to understand the options for legality, accessibility, and efficacy.

Many patients describe overlap across these medicines — altered perception, new associations, meaning-making. The big differences show up in accessibility, controlled substance regulation, mechanism of action, feel, time course, and logistics. Please note that Lumin Health in no way condones the obtaining and use of regulated substances. This is purely for informational purposes only and reflective of the kinds of questions that we hear routinely. 

Mechanisms at a glance (high-level)

• Classic psychedelics (psilocybin/LSD/DMT/iboga): Most prominently engage the 5-HT2A serotonin receptor system.
• Ketamine / esketamine (Spravato): Primarily modulate glutamate via NMDA receptors, cascading to AMPA activity and synaptic plasticity.^[3] See How Ketamine Works for a deeper dive.
• MDMA (empathogen): Increases serotonin, norepinephrine, and dopamine release and often enhances feelings of openness and connection; typically less visual than classic psychedelics.

Mechanism isn’t destiny — but it does inform what sessions feel like and how we prepare.

Typical phenomenology of psychedelics and empathogens; what it tends to feel like

• Classic psychedelics: Often outwardly engaging — colors intensify, patterns breathe, music can feel textured and vast. Thought associations loosen; awe and/or fear can arise.
• Ketamine: More internal and cocoon-like. Visuals may be subtler; many people feel a gentle distance from the body (dissociation) and a kinder vantage point on difficult thoughts. This inwardness is why we at Lumin Health pare back input (eye mask, curated music, privacy) and keep the room quiet.
• MDMA: Typically emotional openness more than visuals — reduced defensiveness, warmth, and easier access to hard topics, which can support talk-based work.

For those familiar with traditional psychedelic compounds, ketamine may feel like it’s in the same neighborhood, but living in a different house — recognizably altered, but guided inward. For a focused look at psilocybin specifically — approval status, legality, evidence, and cost next to ketamine therapy — see our psilocybin vs. ketamine therapy comparison.

Session length and logistics

• Classic psychedelics: Commonly 4–8 hours (route- and dose-dependent), which can mean dedicating most of a day and a specific environment.
• Ketamine therapy: The intense phase is usually ~40–70 minutes, with 30–60 minutes of re-orientation. Many patients appreciate the shorter arc because it fits with work and caregiving. We often plan psychotherapy or behavioral support during the neuroplasticity window to help new learning “stick.”
• Esketamine (Spravato): Delivered in a REMS-governed Spravato clinic, typically twice weekly early on, then tapered. As of January 2025, esketamine can also be used as monotherapy (without a coinciding antidepressant) for certain adults with treatment-resistant depression (previously it had to be used alongside an antidepressant medication), which increases care-planning flexibility.^[4]

Where research and approval status stand — and why Lumin Health is cautious

• Esketamine (Spravato): FDA-approved for specific depressive disorders and provided under clinical monitoring; labeling outlines safety, abuse/diversion risk, and program requirements that clinics must follow.^[1,2]
• Classic psychedelics (psilocybin/LSD/DMT/iboga): Active clinical trials continue, but no FDA approval for depression as of today; state-level reforms do not equal federal approval for medical use. This means that safety and risk management exercises have not been adequately demonstrated as of yet and these compounds are still regarded as federally illegal with no medical use identified.
• MDMA-assisted therapy: The FDA issued a Complete Response Letter in 2024 declining approval and later publicly released its rationale.  Research is ongoing. 

Why our caution? Because responsible care balances promise with proof. We track the data closely and revise protocols when the evidence — and the regulators — support a change. Until then, we anchor on what’s approved, safe, and realistically accessible for people seeking ketamine therapy or ketamine for depression.

Choosing what treatment fits you

You don’t need a perfect label to heal. What matters is fit: the right mechanism for your biology, the right environment for your nervous system, and the right follow-through for your goals. For many, ketamine’s “different house” offers a shorter, inward-leaning path with medical guardrails — either as off-label ketamine therapy or as esketamine in a Spravato program.

References

1. Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. PubMed
2. Fu DJ, Ionescu DF, Li X, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry. 2020;81(3). PubMed
3. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-64. PubMed
4. Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(9):877-887. PubMed
5. Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059-77. PubMed

Take the first step today.

If you or a loved one in Massachusetts and the greater Washington DC/Maryland area is struggling with depression or anxiety, Lumin Health's team of experts is ready to help. Book a free 20-minute consultation to learn if ketamine therapy could be the breakthrough you've been looking for.

Available in Massachusetts and the greater Washington DC/Maryland area.

Book Your Free Consultation

Frequently Asked Questions

Is ketamine the same as DMT, LSD, or other classic psychedelics?

No. Ketamine and esketamine primarily work through the brain's glutamate system, while classic psychedelics like LSD, psilocybin, and DMT mainly engage the serotonin 5-HT2A receptor. That different mechanism is part of why the two experiences tend to feel different, even though people sometimes group them together.

How does ketamine compare to ibogaine for depression?

Esketamine (Spravato) is FDA-approved for treatment-resistant depression and major depression with suicidal thoughts; ibogaine has no FDA approval for any use and remains federally illegal with no accepted medical use in the United States. Ketamine's off-label use for depression, by contrast, is supported by a large body of research and delivered within a psychiatrist-led, monitored framework.

How does ketamine's experience compare to classic psychedelics like psilocybin or LSD?

Ketamine tends to feel more internal and cocoon-like, with subtler visuals and a gentle sense of distance from the body. Classic psychedelics are often described as more outwardly engaging, with intensified colors and looser thought associations. Because of this, care teams create a quiet, low-stimulus room for ketamine sessions rather than the more immersive setting used for classic psychedelics.

Why is a ketamine therapy session shorter than a classic psychedelic session?

A ketamine session's active dosing phase usually runs about 40 to 70 minutes, plus another 30 to 60 minutes of re-orientation afterward, a much shorter total arc than the multi-hour course typical of psilocybin or LSD. That shorter arc means treatment can be scheduled around work and caregiving, with time afterward protected for rest or therapy.

Where does MDMA fit compared to ketamine and classic psychedelics?

MDMA is generally described as an empathogen, meaning it tends to increase openness and connection with fewer visual effects than classic psychedelics. The FDA hasn't approved MDMA-assisted therapy, and it remains federally illegal with no accepted medical use, while esketamine (Spravato) already has FDA approval for treatment-resistant depression.